Targeting Redness Of Rosacea - Investigational Gel Shows Promise In Human Trial

[News Reporter]

At least 16 million Americans suffer from Rosacea, a chronic dermatological skin condition of the face involving persistent redness, flushing, inflammatory lesions and visible blood vessels. An announcement made today by Galderma Pharma S.A., reports positive top-line results from a Phase 2b trial regarding the efficacy and safety of CD07805/47, a proprietary topical gel under investigation for treating patients with moderate to severe facial erythema (redness) of rosacea. Joseph F. Fowler, M.D...

More...